Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-cash Items (2016 - 2025)

Ocular Therapeutix has reported Non-cash Items over the past 11 years, most recently at $10.9 million for Q4 2025.

  • Quarterly results put Non-cash Items at $10.9 million for Q4 2025, down 73.89% from a year ago — trailing twelve months through Dec 2025 was $10.9 million (down 73.89% YoY), and the annual figure for FY2025 was $10.9 million, down 73.89%.
  • Non-cash Items for Q4 2025 was $10.9 million at Ocular Therapeutix, down from $41.6 million in the prior quarter.
  • Over the last five years, Non-cash Items for OCUL hit a ceiling of $41.6 million in Q4 2024 and a floor of $7000.0 in Q4 2022.
  • Median Non-cash Items over the past 5 years was $10.9 million (2025), compared with a mean of $13.8 million.
  • Biggest five-year swings in Non-cash Items: tumbled 99.95% in 2022 and later skyrocketed 47957.14% in 2023.
  • Ocular Therapeutix's Non-cash Items stood at $13.3 million in 2021, then tumbled by 99.95% to $7000.0 in 2022, then skyrocketed by 47957.14% to $3.4 million in 2023, then soared by 1135.73% to $41.6 million in 2024, then plummeted by 73.89% to $10.9 million in 2025.
  • The last three reported values for Non-cash Items were $10.9 million (Q4 2025), $41.6 million (Q4 2024), and $3.4 million (Q4 2023) per Business Quant data.